Transplantation Conditioning
-
Subject Areas on Research
-
A Couple-Based Communication Intervention for Hematopoietic Cell Transplantation Survivors and Their Caregiving Partners: Feasibility, Acceptability, and Change in Process Measures.
-
A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance).
-
A novel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with nonmalignant diseases.
-
A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.
-
A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.
-
A successful unrelated peripheral blood stem cell transplantation with reduced intensity-conditioning regimen in a patient with late-onset purine nucleoside phosphorylase deficiency.
-
ALPS-Like Phenotype Caused by ADA2 Deficiency Rescued by Allogeneic Hematopoietic Stem Cell Transplantation.
-
Active rehabilitation during extracorporeal membrane oxygenation as a bridge to lung transplantation.
-
Acute graft-vs-host disease: pathobiology and management.
-
Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States.
-
Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.
-
Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens.
-
Alemtuzumab for the prevention and treatment of graft-versus-host disease.
-
Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors.
-
Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis.
-
Allogeneic stem cell transplantation with omidubicel in sickle cell disease.
-
Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.
-
An unconditioned bone marrow transplantation in a child with purine nucleoside phosphorylase deficiency and its unique complication.
-
Autologous stem cell transplantation for autoimmune diseases: issues in protocol development.
-
Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience.
-
B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation.
-
B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment?
-
Bloodstream Infection Due to Vancomycin-resistant Enterococcus Is Associated With Increased Mortality After Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study.
-
Bone marrow B cell precursor number after allogeneic stem cell transplantation and GVHD development.
-
Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies.
-
Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.
-
CT-314 Multicenter Long-Term Follow Up of Allogeneic Hematopoietic Stem Cell Transplantation With Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.
-
Can We Cure Light Chain Deposition Disease of the Kidneys?-A Review and Case Report of a Patient Treated With a Triple Transplant Approach.
-
Cardiopulmonary exercise testing prior to myeloablative allo-SCT: a feasibility study.
-
Cardiopulmonary fitness in patients undergoing hematopoietic SCT: a pilot study.
-
Cell therapy for diverse central nervous system disorders: inherited metabolic diseases and autism.
-
Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful.
-
Clinical and Neuroimaging Correlates of Post-Transplant Delirium.
-
Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies.
-
Collaborative multicenter investigation of marrow transplantation for sickle cell disease: current results and future directions.
-
Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation.
-
Comparison of Quality of Life and Outcomes between Haploidentical and Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation.
-
Comparison of non-myeloablative conditioning regimens for lymphoproliferative disorders.
-
Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency.
-
Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine.
-
Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.
-
Complications of allogeneic bone marrow transplantation.
-
Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders.
-
Cord-blood transplants from unrelated donors in Hurler's syndrome.
-
Cord-blood transplants from unrelated donors in patients with Hurler's syndrome.
-
Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis.
-
Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.
-
Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.
-
Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.
-
Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial.
-
Cytomegalovirus in Allogeneic Hematopoietic Transplantation: Impact on Costs and Clinical Outcomes Using a Preemptive Strategy.
-
Development of a protocol for allogeneic marrow transplantation for severe systemic sclerosis: paradigm for autoimmune disease.
-
Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors.
-
Disorders of glucose homeostasis in young adults treated with total body irradiation during childhood: a pilot study.
-
Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation.
-
Durable Chimerism and Long-Term Survival after Unrelated Umbilical Cord Blood Transplantation for Pediatric Hemophagocytic Lymphohistiocytosis: A Single-Center Experience.
-
Durable engraftment and correction of hematological abnormalities in children with congenital amegakaryocytic thrombocytopenia following myeloablative umbilical cord blood transplantation.
-
Effect of cord blood processing on transplantation outcomes after single myeloablative umbilical cord blood transplantation.
-
Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma.
-
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
-
Eighth Annual International Umbilical Cord Blood Transplantation Symposium, San Francisco, California, June 3-5, 2010.
-
Endothelial cell function and endothelial-related disorders following haematopoietic cell transplantation.
-
Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases.
-
Evaluating immune response and metabolic related biomarkers pre-allogenic hematopoietic stem cell transplant in acute myeloid leukemia.
-
FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.
-
Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission.
-
Feasibility of frequent patient-reported outcome surveillance in patients undergoing hematopoietic cell transplantation.
-
Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors.
-
Fertility challenges for women with sickle cell disease.
-
Financial incentives to increase stool collection rates for microbiome studies in adult bone marrow transplant patients.
-
Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.
-
Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics.
-
Gene expression signatures that predict radiation exposure in mice and humans.
-
Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans.
-
Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
-
Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplantation Candidates Age 18 to 80 Years.
-
Health-related quality of life in reduced-intensity hematopoietic cell transplantation based on donor availability in patients aged 50-75 with advanced myelodysplastic syndrome: BMT CTN 1102.
-
Hematopoietic Stem Cell Transplantation for CD40 Ligand Deficiency: Single Institution Experience.
-
Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.
-
Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors.
-
Hematopoietic stem cell transplantation for complete IFN-gamma receptor 1 deficiency: a multi-institutional survey.
-
Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2.
-
Hematopoietic stem cell transplantation.
-
Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.
-
Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.
-
High dose chemotherapy with autologous peripheral blood progenitor cell transplantation in an anephric child with multiply recurrent Wilms tumor.
-
High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma.
-
High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.
-
High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma.
-
Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation.
-
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
-
Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012.
-
Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome.
-
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.
-
Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research.
-
In utero hematopoietic stem cell transplants prolong survival of postnatal kidney transplantation in monkeys.
-
In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial.
-
Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1.
-
Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease.
-
Indications and donor selections for allogeneic stem cell transplantation in children with hematologic malignancies.
-
International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma.
-
Is autologous stem cell transplantation still relevant for multiple myeloma?
-
Lack of isohemagglutinin production following minor ABO incompatible unrelated HLA mismatched umbilical cord blood transplantation.
-
Late Effects after Umbilical Cord Blood Transplantation in Very Young Children after Busulfan-Based, Myeloablative Conditioning.
-
Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors.
-
Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma.
-
Long-Term Functional Outcomes after Hematopoietic Stem Cell Transplant for Early Infantile Krabbe Disease.
-
Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis.
-
Long-term follow-Up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia.
-
Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin.
-
Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism.
-
Longterm followup and quality of life after hematopoietic stem cell transplantation.
-
Lymphocyte reconstitution following non-myeloablative hematopoietic stem cell transplantation follows two patterns depending on age and donor/recipient chimerism.
-
Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006).
-
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.
-
Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
-
Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research.
-
Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine?
-
Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry.
-
Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.
-
Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures.
-
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.
-
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
-
Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients.
-
Myeloablative transplantation using either cord blood or bone marrow leads to immune recovery, high long-term donor chimerism and excellent survival in chronic granulomatous disease.
-
Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.
-
Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation.
-
Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation.
-
Non-myeloablative umbilical cord blood transplantation.
-
Nonmyeloablative allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors: a review.
-
Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells.
-
Ocular toxicity following high dose chemotherapy and autologous transplant.
-
One-unit versus two-unit cord-blood transplantation for hematologic cancers.
-
Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome.
-
Outcomes after Unrelated Umbilical Cord Blood Transplantation for Children with Osteopetrosis.
-
Outcomes after hematopoietic stem cell transplantation for children with I-cell disease.
-
Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression.
-
Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation.
-
Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning.
-
Outcomes of pediatric patients with therapy-related myeloid neoplasms.
-
Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning.
-
Outcomes of unrelated umbilical cord blood transplantation for X-linked adrenoleukodystrophy.
-
Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial.
-
Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
-
Pediatric hematopoietic stem cell transplantation and the role of imaging.
-
Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.
-
Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients.
-
Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease.
-
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.
-
Pitfalls and Successes in Trials in Older Transplant Patients with Hematologic Malignancies.
-
Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.
-
Polyclonal long-term MFGS-gp91phox marking in rhesus macaques after nonmyeloablative transplantation with transduced autologous peripheral blood progenitor cells.
-
Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.
-
Posttransplant autoimmune hemolytic anemia and other autoimmune cytopenias are increased in very young infants undergoing unrelated donor umbilical cord blood transplantation.
-
Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation.
-
Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment.
-
Prevalence of self-reported sleep dysfunction before allogeneic hematopoietic cell transplantation.
-
Progress toward less toxic conditioning.
-
Pulmonary Complications in Pediatric and Adolescent Patients Following Allogeneic Hematopoietic Cell Transplantation.
-
Quantitative measures of physical functioning after autologous hematopoietic stem cell transplantation in multiple myeloma: a feasibility study.
-
Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease.
-
Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901.
-
Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies.
-
Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002).
-
Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation in the scleroderma: cyclophosphamide or transplantation trial.
-
Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors.
-
Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia.
-
Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia.
-
Results of the cord blood transplantation study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases.
-
Results of unrelated cord blood transplant in fanconi anemia patients: risk factor analysis for engraftment and survival.
-
Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.
-
Revisiting a single day salvage conditioning following graft failure.
-
Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome.
-
Risk factors for acute GVHD and survival after hematopoietic cell transplantation.
-
Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma.
-
Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors.
-
Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation.
-
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy.
-
Stem cell transplantation for multiple myeloma.
-
Stem-cell transplantation for chronic granulomatous disease.
-
Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation.
-
Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen.
-
Successful bone marrow transplantation with reduced intensity conditioning in a patient with delayed-onset adenosine deaminase deficiency.
-
Successful reduced intensity hematopoietic cell transplant in a patient with deficiency of adenosine deaminase 2.
-
Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.
-
Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia.
-
The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases.
-
The Knife's Edge of Tolerance: Inducing Stable Multilineage Mixed Chimerism but With a Significant Risk of CMV Reactivation and Disease in Rhesus Macaques.
-
Theory-driven development of a medication adherence intervention delivered by eHealth and transplant team in allogeneic stem cell transplantation: the SMILe implementation science project.
-
Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia.
-
Transplantation of a child with sickle cell anemia with an unrelated cord blood unit after reduced intensity conditioning.
-
Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease.
-
Transplantation outcomes for severe combined immunodeficiency, 2000-2009.
-
Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft.
-
Treatment of infants with complete DiGeorge anomaly.
-
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.
-
Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes.
-
Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment.
-
Umbilical cord blood transplantation for children with thalassemia and sickle cell disease.
-
Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens.
-
Umbilical cord stem cell transplantation.
-
Unmanipulated or CD34 selected haplotype mismatched transplants.
-
Unrelated umbilical cord blood transplantation in adult patients.
-
Utility of Autopsy among Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients: One Last Chance to Learn?
-
Value of surgical resection in children with high-risk neuroblastoma.
-
Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy.
-
Keywords of People